As of June 9, 2025, Seagen Inc (SGEN) reports a Net Margin of -31.10%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Seagen Inc's Net Margin
Over recent years, Seagen Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2022-12-31 | -31.10% |
| 2021-12-31 | -42.84% |
| 2020-12-31 | 28.21% |
| 2019-12-31 | -17.31% |
| 2018-12-31 | -34.02% |
This slight upward trend highlights how Seagen Inc manages its overall profitability and cost control over time.
Comparing Seagen Inc's Net Margin to Peers
To better understand Seagen Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Seagen Inc (SGEN) | -31.10% |
| Halozyme Therapeutics Inc (HALO) | 43.74% |
| United Therapeutics Corp (UTHR) | 41.53% |
| CureVac NV (CVAC) | 30.30% |
| Alkermes Plc (ALKS) | 23.56% |
| Sarepta Therapeutics Inc (SRPT) | 12.37% |
Compared to its competitors, Seagen Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.